Biopharmaceutical compositions and related methods
The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.
1. An antigen binding protein comprising a heavy chain variable region having the CDRH1 amino acid sequence shown in SEQ ID NO: 5, the CDRH2 amino acid sequence shown in SEQ ID NO: 6, and the CDRH3 amino acid sequence shown in SEQ ID NO: 7; and a light chain variable region having the CDRL1 amino acid sequence shown in SEQ ID NO: 8, the CDRL2 amino acid sequence shown in SEQ ID NO: 9, and the CDRL3 amino acid sequence shown in SEQ ID NO: 10.
2. The antigen binding protein of claim 1 wherein the heavy chain variable region further comprises a heavy chain FR4 amino acid sequence as shown in SEQ ID NO: 21.
3. The antigen binding protein of claim 2 comprising a heavy chain Fc domain having a tyrosine residue at position 252 , a threonine residue at position 254 and a glutamic acid residue at position 256 and wherein an amino terminus of the heavy chain Fc domain is connected to a carboxy terminus of the heavy chain variable region, wherein the Fc domain is comprised of a human IgG 1 Fc domain.
4. An antigen binding protein comprising a heavy chain variable region sequence having the amino acid sequence shown in SEQ ID NO: 3; and a light chain variable region sequence having the amino acid sequence shown in SEQ ID NO: 4.
5. The antigen binding protein of claim 4 comprising a heavy chain Fc domain having a tyrosine residue at position 252 , a threonine residue at position 254 and a glutamic acid residue at position 256 and wherein an amino terminus of the heavy chain Fc domain is connected to a carboxy terminus of the heavy chain variable region, wherein the Fc domain is comprised of a human IgG 1 Fc domain.
6. An antibody comprising a heavy chain and a light chain, wherein
a) the heavy chain comprises a heavy chain variable region having the CDRH1 amino acid sequence shown in SEQ ID NO: 5, the CDRH2 amino acid sequence shown in SEQ ID NO: 6, and the CDRH3 amino acid sequence shown in SEQ ID NO: 7; and
b) the light chain comprises a light chain variable region having the CDRL1 amino acid sequence shown in SEQ ID NO: 8, the CDRL2 amino acid sequence shown in SEQ ID NO: 9, and the CDRL3 amino acid sequence shown in SEQ ID NO: 10.
7. The antibody of claim 6 wherein the heavy chain variable region further comprises a heavy chain FR4 amino acid sequence as shown in SEQ ID NO: 21.
8. The antibody of claim 7 wherein the heavy chain comprises a heavy chain Fc domain having a tyrosine residue at position 252 , a threonine residue at position 254 and a glutamic acid residue at position 256 , wherein the Fc domain is comprised of a human IgG 1 Fc domain.
9. An antibody comprising a heavy chain and a light chain, wherein
a) the heavy chain comprises a heavy chain variable region sequence having the amino acid sequence shown in SEQ ID NO: 3; and
b) the light chain comprises a light chain variable region sequence having the amino acid sequence shown in SEQ ID NO: 4.
10. The antibody of claim 9 wherein the heavy chain comprises a heavy chain Fc domain having a tyrosine residue at position 252 , a threonine residue at position 254 and a glutamic acid residue at position 256 , wherein the Fc domain is comprised of a human IgG 1 Fc domain.
11. An antibody comprising a heavy chain having the amino acid sequence shown in SEQ ID NO: 1 and a light chain having the amino acid sequence shown in SEQ ID NO: 2.